Medical News

RSS

911 program aims to reduce ER visits

USA Today reports on a 911 pilot program that aims to reduce unnecessary trips to the emergency rooms.

2 Jun 2010

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

DARA BioSciences, Inc. today announced that, on May 28 2010, NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement as set forth in NASDAQ Listing Rule 5550(a)(2). On May 26, 2010, the Company's closing bid price was $3.58 per share, the tenth consecutive day it had been above $1 per share.

2 Jun 2010

Businesses fret penalties, seek opportunities in health overhaul

Some small businesses may get financial help as part of the health overhaul that could cover up to 35 percent of business's premium costs for insuring employees in the form of new tax credits, Kaiser Health News explains in a consumer column.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

Firms chase opportunities in online medicine

General Electric Co. chief executive Jeffrey Immelt urged Japan, at a conference in Tokyo Monday, to use health information technology to improve home-based health care as a hedge against the strains of an aging population, The Wall Street Journal reports. Japan's over-65 population is growing, and could top 30 percent by 2030.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Paid parental leave in Australia may soon be a reality

Australia’s Liberal opposition has allowed the Rudd government to implement the paid parental leave scheme with effect from 1st January 2011. As per this scheme both parents will get an 18 weeks' paid leave at the minimum wage rate of $543 a week. At present Australia is one of the only two OECD countries that does not have a paid parental scheme.

1 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

AMA President to unveil multi-million dollar ad campaign

Today, the 21 percent Medicare physician payment cut goes into effect, leaving health care for seniors and military families in jeopardy. On June 3, AMA President J. James Rohack, MD, will hold a telephone news conference to unveil a multi-million dollar AMA ad campaign urging Americans to call their senators to help avoid a Medicare meltdown.

1 Jun 2010

Consent forms for research: Have they improved in 25 years?

The consent forms that people sign before participating in research are widely considered difficult to understand and sometimes inaccurate. The lack of clarity was implicated in a high-profile legal settlement in April between Arizona State University and a Native American tribe, which claimed that blood samples that its members provided for genetic research were used for purposes not stated in the consent form. Efforts have been made to improve the forms, but how effective are they?

1 Jun 2010

NanoPowers announces closing of CHF 5 million series A financing

NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing. The financing round was led by Novartis Venture Funds. Also participating in the financing were Initiative Capital Romandie and Gran Plasa SA.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

First Edition: June 1, 2010

A number of today's headlines focus on the continuing role of health reform in national political calculations and strategies.

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

PAREXEL International establishes new brand identity "Right Where You Need Us"

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.

From Parexel 1 Jun 2010

OrthoDynamix releases disposable biter for meniscal shoulder, knee repair

OrthoDynamix announces a line extension to their sports medicine portfolio. The ArthroSteer Biter is the first ever disposable biter used for meniscal shoulder and knee repair. A sharp jaw for every procedure affords the ultimate tissue interaction. Moreover, the Biter is steerable, allowing access to and around joint capsule structures.

1 Jun 2010

New walk-in medical center opened in Duane Reade Pharmacy

If you have never been to a walk-in medical center at the local drugstore, you just might soon. Walk-in medical centers are already located in about 1,000 retail locations across the country, and experts say that number could easily double or more within five years.

1 Jun 2010